Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2013 1
2014 4
2015 3
2016 1
2017 3
2018 2
2019 7
2020 14
2021 19
2022 11
Text availability
Article attribute
Article type
Publication date

Search Results

57 results
Results by year
Filters applied: . Clear all
Page 1
Chronic kidney disease.
Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Kalantar-Zadeh K, et al. Among authors: neuen bl. Lancet. 2021 Aug 28;398(10302):786-802. doi: 10.1016/S0140-6736(21)00519-5. Epub 2021 Jun 24. Lancet. 2021. PMID: 34175022 Review.
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V. Toyama T, et al. Among authors: neuen bl. Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4. Diabetes Obes Metab. 2019. PMID: 30697905 Free article.
Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.
Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, Langkilde AM, Mahaffey KW, McGuire DK, Neal B, Perkovic V, Pong A, Sabatine MS, Raz I, Toyama T, Wanner C, Wheeler DC, Wiviott SD, Zinman B, Heerspink HJL. Neuen BL, et al. Circulation. 2022 May 10;145(19):1460-1470. doi: 10.1161/CIRCULATIONAHA.121.057736. Epub 2022 Apr 8. Circulation. 2022. PMID: 35394821 Free article.
Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease: Results From the CREDENCE Trial and Meta-Analysis.
Zhou Z, Jardine MJ, Li Q, Neuen BL, Cannon CP, de Zeeuw D, Edwards R, Levin A, Mahaffey KW, Perkovic V, Neal B, Lindley RI; CREDENCE Trial Investigators*. Zhou Z, et al. Among authors: neuen bl. Stroke. 2021 May;52(5):1545-1556. doi: 10.1161/STROKEAHA.120.031623. Epub 2021 Apr 20. Stroke. 2021. PMID: 33874750 Free PMC article. Clinical Trial.
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, Cannon CP, Charytan DM, Edwards R, Górriz JL, Jardine MJ, Levin A, Neal B, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Mahaffey KW, Heerspink HJL. Neuen BL, et al. Eur Heart J. 2021 Dec 21;42(48):4891-4901. doi: 10.1093/eurheartj/ehab497. Eur Heart J. 2021. PMID: 34423370 Clinical Trial.
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis.
Jardine M, Zhou Z, Lambers Heerspink HJ, Hockham C, Li Q, Agarwal R, Bakris GL, Cannon CP, Charytan DM, Greene T, Levin A, Li JW, Neuen BL, Neal B, Oh R, Oshima M, Pollock C, Wheeler DC, de Zeeuw D, Zhang H, Zinman B, Mahaffey KW, Perkovic V. Jardine M, et al. Among authors: neuen bl. Clin J Am Soc Nephrol. 2021 Mar 8;16(3):384-395. doi: 10.2215/CJN.15260920. Epub 2021 Feb 22. Clin J Am Soc Nephrol. 2021. PMID: 33619120 Free PMC article. Clinical Trial.
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
Oshima M, Neuen BL, Li J, Perkovic V, Charytan DM, de Zeeuw D, Edwards R, Greene T, Levin A, Mahaffey KW, De Nicola L, Pollock C, Rosenthal N, Wheeler DC, Jardine MJ, Heerspink HJL. Oshima M, et al. Among authors: neuen bl. J Am Soc Nephrol. 2020 Dec;31(12):2925-2936. doi: 10.1681/ASN.2020050723. Epub 2020 Sep 30. J Am Soc Nephrol. 2020. PMID: 32998938 Free PMC article. Clinical Trial.
57 results